EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
In brief
EU regulators are poised to approve the first PD‑1 inhibitor plus antibody‑drug conjugate combo for bladder cancer, based on strong Phase 3 data.